[Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates].
In the last thirty years, factor VIII concentrates have been the mainstay of hemophilia treatment, first as wet cryoprecipitate and later as dry concentrates commercially available. The evidence of a high risk of blood-born virus transmission by these products provoked the development of new methods for virus inactivation. We report these methods with special attention to their safety, and mention the new perspectives of treatment with recombinant DNA FVIII:C and ultimately by gene insertion therapy.
Tavares
A
A
Serviço Imuno.Hemoterapia, Hospital de Santa Maria, Lisboa.
Galvão
M
M
D005169:Factor VIII / Q000009:adverse effects* / Q000627:therapeutic use; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans; D008722:Methods; D014777:Virus Diseases / Q000209:etiology / Q000517:prevention & control*
D005169:Factor VIII
Segurança terapêutica na hemofilia A. Inactivação viral dos concentrados de FVIII:C.